200132-83-8|春雷霉素盐酸盐一水合物|Kasugamycin hydrochloride hydrate|MFCD00149375-范德生物科技公司

春雷霉素盐酸盐一水合物

NMR下载 COA and HPLC MSDS下载
names：
Kasugamycin hydrochloride hydrate
CAS号：
200132-83-8
MDL Number： MFCD00149375
MF(分子式)： C14H28ClN3O10 MW(分子量)： 433.84
EINECS: Reaxys Number:
Pubchem ID:57369825 Brand:BIOFOUNT

春雷霉素盐酸盐一水合物(00132-83-8,Kasugamycin hydrochloride hydrate,Ksg hydrochloride hydrate)是一种既能结合30s和70s核糖体又不能结合50s亚基的抗生素。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000177-500mg	500mg	97.91%	¥ 487.50	¥ 487.50		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	春雷霉素盐酸盐一水合物(00132-83-8);盐酸春日霉素水合物; 2-氨基-2-[（（2R，3S，5S，6R）-5-氨基-2-甲基-6-[（2S，3S，5S，6R）-2,3,4,5,6-五羟基环己基]氧杂-3-基]亚氨基乙酸;水合物;盐酸盐;UNII-5A9BN7V7QL;5A9BN7V7QL;SCHEMBL69506;
英文别名	Kasugamycin hydrochloride hydrate(00132-83-8);,Ksg hydrochloride hydrate;2-amino-2-[(2R,3S,5S,6R)-5-amino-2-methyl-6-[(2S,3S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyoxan-3-yl]iminoacetic acid;hydrate;hydrochloride;UNII-5A9BN7V7QL;5A9BN7V7QL;SCHEMBL69506;
CAS号	200132-83-8
SMILES	OC(C(N[C@@H](C[C@@H]1N)[C@@H](C)O[C@]1([H])O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]2O)=N)=O.[H]Cl.O
Inchi	InChI=1S/C14H25N3O9.ClH.H2O/c1-3-5(17-12(16)13(23)24)2-4(15)14(25-3)26-11-9(21)7(19)6(18)8(20)10(11)22;;/h3-11,14,18-22H,2,15H2,1H3,(H2,16,17)(H,23,24);1H;1H2/t3-,4+,5+,6-,7+,8+,9-,10+,11+,14-;;/m1../s1
InchiKey	URDOPMVCASNBEZ-IYWSOWMLSA-N
分子式 Formula	C14H28ClN3O10
分子量 Molecular Weight	433.84
闪点 FP
熔点 Melting point	203°C
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure	<1.3X10-4 mm Hg在25°C
溶解度Solubility	生物体外In Vitro:DMSO溶解度14.33 mg/mL(33.03 mM;Need ultrasonic and warming)
性状	无色透明液体
储藏条件 Storage conditions	存放在阴凉干燥处，短期（数天至数周）在0-4℃，长期（数月至数年）在-35℃。

春雷霉素盐酸盐一水合物(00132-83-8,Kasugamycin hydrochloride hydrate,Ksg hydrochloride hydrate)解毒剂和紧急治疗

Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

春雷霉素盐酸盐一水合物(00132-83-8,Kasugamycin hydrochloride hydrate,Ksg hydrochloride hydrate)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags：春雷霉素盐酸盐一水合物试剂,春雷霉素盐酸盐一水合物杂质,春雷霉素盐酸盐一水合物中间体,春雷霉素盐酸盐一水合物密度,春雷霉素盐酸盐一水合物合成,春雷霉素盐酸盐一水合物溶解度,春雷霉素盐酸盐一水合物旋光度,春雷霉素盐酸盐一水合物闪点,春雷霉素盐酸盐一水合物熔点,春雷霉素盐酸盐一水合物购买,

产品说明	春雷霉素盐酸盐一水合物(00132-83-8,Ksg hydrochloride hydrate)是结合30S和70S核糖体但不分离50S亚基的抗生素。
Introduction	春雷霉素盐酸盐一水合物(00132-83-8,Ksg hydrochloride hydrate)is an antibiotic which binds both the 30S and 70S ribosome but not isolated 50S subunits.
Application1	盐酸春日霉素水合物（Ksg盐酸水合物）模拟mRNA核苷酸以破坏tRNA结合并抑制规范翻译起始
Application2	Kasugamycin hydrochloride hydrate mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation.
Application3

春雷霉素盐酸盐一水合物(00132-83-8,Kasugamycin hydrochloride hydrate,Ksg hydrochloride hydrate)药理学：

春雷霉素盐酸盐一水合物是一种氨基糖苷类抗生素，春雷霉素盐酸盐一水合物通过与30S核糖体亚基相互作用来抑制蛋白质合成。春雷霉素盐酸盐一水合物抑制蛋白质合成的机制似乎与其他氨基糖苷类（如链霉素，卡那霉素）不同。

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

雷霉素盐酸盐一水合物(00132-83-8,Kasugamycin hydrochloride hydrate,Ksg hydrochloride hydrate)危害处理：

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

Schluenzen F, et al. The antibiotic kasugamycin mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation. Nat Struct Mol Biol. 2006 Oct;13(10):871-8.

Schuwirth BS, et al. Structural analysis of kasugamycin inhibition of translation. Nat Struct Mol Biol. 2006 Oct;13(10):879-86.

春雷霉素盐酸盐一水合物(00132-83-8,Kasugamycin hydrochloride hydrate,Ksg hydrochloride hydrate)参考文献：

1、Structural analysis of kasugamycin inhibition of translation
Barbara S Schuwirth 1, J Michael Day, Cathy W Hau, Gary R Janssen, Albert E Dahlberg, Jamie H Doudna Cate, Antón Vila-Sanjurjo

Abstract The prokaryotic ribosome is an important target of antibiotic action. We determined the X-ray structure of the aminoglycoside kasugamycin (Ksg) in complex with the Escherichia coli 70S ribosome at 3.5-A resolution. The structure reveals that the drug binds within the messenger RNA channel of the 30S subunit between the universally conserved G926 and A794 nucleotides in 16S ribosomal RNA, which are sites of Ksg resistance. To our surprise, Ksg resistance mutations do not inhibit binding of the drug to the ribosome. The present structural and biochemical results indicate that inhibition by Ksg and Ksg resistance are closely linked to the structure of the mRNA at the junction of the peptidyl-tRNA and exit-tRNA sites (P and E sites).

2、The antibiotic kasugamycin mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation
Frank Schluenzen 1, Chie Takemoto, Daniel N Wilson, Tatsuya Kaminishi, Joerg M Harms, Kyoko Hanawa-Suetsugu, Witold Szaflarski, Masahito Kawazoe, Mikako Shirouzu, Knud H Nierhaus, Shigeyuki Yokoyama, Paola Fucini

Abstract Kasugamycin (Ksg) specifically inhibits translation initiation of canonical but not of leaderless messenger RNAs. Ksg inhibition is thought to occur by direct competition with initiator transfer RNA. The 3.35-A structure of Ksg bound to the 30S ribosomal subunit presented here provides a structural description of two Ksg-binding sites as well as a basis for understanding Ksg resistance. Notably, neither binding position overlaps with P-site tRNA; instead, Ksg mimics codon nucleotides at the P and E sites by binding within the path of the mRNA. Coupled with biochemical experiments, our results suggest that Ksg indirectly inhibits P-site tRNA binding through perturbation of the mRNA-tRNA codon-anticodon interaction during 30S canonical initiation. In contrast, for 70S-type initiation on leaderless mRNA, the overlap between mRNA and Ksg is reduced and the binding of tRNA is further stabilized by the presence of the 50S subunit, minimizing Ksg efficacy.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开